Health
Neuren Pharmaceuticals secures European approval for DAYBU (trofinetide) drug
Neuren Pharmaceuticals (ASX:NEU) secured European Commission marketing authorisation for DAYBU (trofinetide).
Jon Cuthbert
Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Contact
Contact editorial teamArticles by Jon Cuthbert
Cryptocurrency
Bitcoin tops $80K as Hayes calls bull market
Bitcoin (CRYPTO:BTC) rose above $80,000 as Arthur Hayes said expanded Treasury buybacks marked a new bull market.
Infrastructure
Vulcan Steel reports NZ$129.3 million annual EBITDA
Vulcan Steel (ASX:VSL) announced its financial results for the year ended June 30, delivering an operating cash flow of NZ$73 million.
Cryptocurrency
Bitcoin study finds 47% rise in desired allocation
Bitcoin (CRYPTO:BTC) remains poorly understood by many US households, according to a Cleveland Fed study.
Financial
Pay.com.au raises US$28M for US expansion
Pay.com.au raised US$28 million in Series E capital to expand its payment services into the US market.
Mining
Brightstar Resources finds 500m gold zone in Two Mile Hill deposit
Brightstar Resources (ASX:BTR) reported intersecting up to 500m of mineralised tonalite containing visible gold at its Two Mile Hill deposit.
Cryptocurrency
CleanCore sells $33.4M Dogecoin stake
CleanCore Solutions sold substantially all 463 million Dogecoin (CRYPTO:DOGE) for about US$33.4 million.
Health
Integral Diagnostics reports $788.7M FY26 revenue
Integral Diagnostics (ASX:IDX) announced its financial results for the year ended June 30, delivering an operating net profit after tax of $47.4 million.
Cryptocurrency
Bitcoin trader opens $23M short
Bitcoin (CRYPTO:BTC) faced another short bet worth US$23.13 million after a trader lost US$4.56 million.
Property
Cedar Woods delivers record $65.6M FY26 profit
Cedar Woods (ASX:CWP) reported a record full-year net profit after tax of $65.6 million for FY26, up 36%.